Xuanzhu Biopharmaceutical Co Ltd
Company Profile
Business description
Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China’s pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with proven druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology and high growth potential therapeutic areas such as NASH.
Contact
Zhubang 2000 Business Center
2107, Building 2
Balizhuang Xili
Chaoyang District
Beijing
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
342
Stocks News & Analysis
stocks
Jet fuel price spike weighing on Australian airline profits
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,173.60 | 49.60 | -0.54% |
| CAC 40 | 8,322.87 | 48.30 | 0.58% |
| DAX 40 | 24,240.51 | 173.81 | 0.72% |
| Dow JONES (US) | 48,463.72 | 72.27 | -0.15% |
| FTSE 100 | 10,639.91 | 80.33 | 0.76% |
| HKSE | 26,394.26 | 446.94 | 1.72% |
| NASDAQ | 24,016.02 | 376.94 | 1.59% |
| Nikkei 225 | 59,518.34 | 1,384.10 | 2.38% |
| NZX 50 Index | 13,066.06 | 10.52 | -0.08% |
| S&P 500 | 7,022.95 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,955.00 | 62.20 | -0.69% |
| SSE Composite Index | 4,055.55 | 28.34 | 0.70% |